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Abstract
Background: Targeted therapies for cancer, especially the malignant cancer, are always restricted by the deficiency
of tumor-specific drug delivery methods. Subtilase cytotoxic is a virulent cytotoxin, and the subunit A (SubA) of it
is able to destroy the structure of glucose-regulated protein 78 (GRP78) to induce cell apoptosis, and to be expected as
anti-cancer drugs, however, the ubiquitous receptor of subunit B of Subtilase cytotoxic (SubB) restricts its application
on cancer therapy.
Results: The present study constructed and expressed a fusion protein of GBP-SubA in E. coli Rosetta
(DE3) system, in which the subunit B of Subtilase cytotoxic was replaced by GRP78 binding peptide
(GBP). The fusion protein was expressed in inclusion body form. Subsequently, the denaturation/renaturation process
and Ni-column purification were performed. Our data indicated the purified GBP-SubA could bind GRP78 existed on
cancer cell surface specifically, internalize into cells to inactivate intracellular GRP78 and induce apoptosis.
Moreover, the apoptosis induction effect of GBP-SubA was enhanced obviously along with the increased cancer
cell surface GBP78.
Conclusions: It indicates that the recombinant GBP-SubA possesses the dual functions of GBP and SubA to
induce cancer cell apoptosis specifically, revealing that GBP-SubA holds important implications for developing as
an anti-cancer peptide drug.
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Abbreviations: Bip, Immunoglobulin heavy chain binding protein; DAPI, 4, 6-diamidino-2-phenylindole
dihydrochloride; ER, Endoplasmic reticulum; GBP, GRP78 binding peptide; GRP78, Glucose-regulated protein 78;
IPTG, Isopropyl-β-D-thiogalactopyranoside; PBS, Phosphate buffered saline; PVDF, Polyvinylidene difluoride;
SubA, Subunit A of Subtilase cytotoxic; TRITC, Tetramethylrhodamineisothiocyanate
Background
Glucose-regulated protein 78 (GRP78), also known as
the immunoglobulin heavy chain binding protein (BiP),
is a member of the heat-shock chaperon family that
mainly resides in endoplasmic reticulum (ER) [1]. In
normal cells, GRP78 is considered as an important
regulator of ER homeostasis because of its roles in pro-
tein folding and assembly, targeting misfolded proteins
for degradation, controlling the activation of the ER
transmembrane sensor proteins and maintenance of
Ca2+ homeostasis [2]. Accumulated reports have shown
the cancer cells usually suffer hypoxia, acidosis and glu-
cose deprivation, which often induce ER stress and
GRP78 high expression [3, 4].
The excessive GRP78 expression is associated with
tumor cell apoptosis resistance [5], drug resistance [6],
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metastasis [7] and metabolic reprogramming [8]. De-
creasing the expression or disabling the function of
GRP78 can promote the apoptosis and inhibit tumor
growth [9]. More importantly, the cancer cell surface
GRP78 is increased along with stressful conditions [10, 11].
In addition, the cell surface GRP78 often presents in the
form of clustering or punctate aggregates that deals with
carcinogenesis [12]. All of these characters suggest that the
GRP78 is capable to serve as a receptor and target of anti-
tumor drugs.
Current antitumor chemotherapeutic drug is often
limited by severe side effects that leave patients under
extreme distress. To increase the delivery efficiency and
decrease undesirable side effects, it is essential to de-
velop new method that facilitate the cancer cell-specific
delivery of therapeutic agents. Recently, peptide ligands
have gained increasing attention for their specific cell
targeting and the delivery of payloads into the target
cells [13, 14]. GRP78 binding peptide (GBP: WIFP-
WIQL) consisted of eight amino acids was designed by
Marco and his colleagues, which was able to specifically
bind to tumor cell surface GRP78, and deliver the fused
pro-apoptotic protein into the tumor cells to suppress
tumor growth [15]. Therefore, GBP is very suitable as
the vehicle of cytotoxic agents to suppress tumor growth
with fewer side effects.
Subtilase cytotoxic is the most recently discovered in
the Shiga toxigenic Escherichia coli (STEC) O113:H21
strain 98NK2, and it is a member of AB5 toxins family
[16, 17]. The Subtilase cytotoxic holotoxin is composed
of one 35 kD catalytic A subunit (SubA) and five 13 kD
B subunits (SubB). SubB can bind to glycan receptors
(Neu5Gc) that universally exist on mammalian cell sur-
face, and SubB is necessary for internalization of the
holotoxin. SubA is the catalytic subunit, its serine pro-
tease activity is responsible for toxicity to the host cells
[18]. Moreover, SubA possesses the extreme substrate
specificity. The analysis from proteomics and functional
studies reveals that GRP78 is the specific molecular tar-
get for SubA. It cleaves GRP78 between the amino acid
residues Leu416 and Leu417 that locate within the hinge
region between the ATPase and COOH-terminal pro-
tein binding domains [19]. The cleavage at this site
leads to loss of GRP78 function and exerts fatal conse-
quences for the cells [20].
Here, a fusion protein GBP-SubA was constructed
and obtained from inclusion bodies through denatur-
ation and renaturation process. The experiment con-
firmed that the fusion protein kept the native features
of GBP and SubA simultaneously. It possessed dual effi-
cacy of targeting and killing tumor cells by against
GRP78 only, but with less effect on normal cells. This




Plasmid pET-28a was preserved in our laboratory. Taq
DNA polymerase, DNA Ligation Kit, and restriction
enzymes were obtained from Takara Biotech Co., Ltd.
(Dalian, China). The Plasmid Mini Kit and Gel Extrac-
tion Kit were purchased from Omega (Norcross, USA).
RPMI-1640 medium and DMEM/F12 (1:1) medium
were from Hyclone (Logan, USA). Fetal bovine serum
(FBS) was from Sangon biotech (Shanghai, China).
Antibodies for His-tag and GRP78 were purchased
from Proteintech (Wuhan, China). Antibody for GRP78
N-terminal was from Beyotime Biotechnology (Shanghai,
China). Phycoerythrin-conjugated secondary antibody was
obtained from Santa Cruz Biotechnology (Dallas, USA).
Rhodamine Phalloidin was purchased from Cytoskel-
eton (Denver, USA). Guava Nexin Reagent and polyvi-
nylidene difluoride (PVDF) membrane were from
Millipore (Darmstadt, Germany). BCA protein assay
kit and Immunol Staining Fix Solution were from
Beyotime (Jiangsu, China). Enhanced chemilumines-
cence detection kit was from Engreen (Beijing, China).
All other chemicals and reagents were obtained from
Sigma (St. Louis, USA).
Cell lines and strains
Human cell lines DLD1, HepG2 and HL-7702 were ob-
tained from the Cell Bank of the Chinese Academy of
Sciences (Shanghai, China). DLD1 and HepG2 cells were
grown at 37 °C in RPMI-1640 medium supplemented
with 10 % heat inactivated FBS, 50 IU penicillin and 50
μg/mL streptomycin. HL-7702 cells were grown at 37 °C
in DMEM/F12 (1:1) medium supplemented with 10 %
heat inactivated FBS, 50 IU penicillin and 50 μg/mL
streptomycin. The Escherichia coli strains DH5α, BL21
(DE3) and Rosetta (DE3) were preserved in our labora-
tory and stored in Luria-Bertani (LB) medium containing
15 % glycerol at −80 °C.
Recombinant plasmid construction
The DNA encoding GBP (WIFPWIQL) and SubA (Gene
ID: 3654564) were fused and synthesized by TaKaRa
Biotechnology (Dalian, China), and the restriction sites
of Bam HI and Xho I were separately introduced to 5′
and 3′ ends of the fused DNA. The synthesized GBP-
SubA DNA segment was ligated into T-Vector pMD19
(TaKaRa, Dalian, China). The recombinant plasmid
pMD19-GBP-SubA and plasmid pET-28a were digested
using Bam HI and Xho I in buffer K at 30 °C for 2 h.
After gel extraction and purification, GBP-SubA DNA
segment was ligated into pET-28a vector using DNA
Ligation Kit with a ratio of insert: vector = 5:1 (mol/
mol) as the user manual. Recombinant pET-28a-GBP-
SubA was transformed into E. coli Rosetta (DE3) cells.
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Cells were grown overnight at 37 °C on LB plates with
kanamycin. Positive colonies were identified by colony
PCR and restriction digestion, and verified by DNA se-
quencing (Sangon, Shanghai, China).
Expression of the recombinant protein
Six histidine-tagged fusion protein GBP-SubA was
expressed in the host strain E. coli Rosetta (DE3) cells.
Briefly, E. coli Rosetta (DE3) cells containing pET-28a-
GBP-SubA were streaked on a LB-agar plate containing
50 μg/mL kanamycin and incubated overnight at 37 °C.
A single colony from the plate was picked and inocu-
lated into 15 mL LB-broth supplemented with 50 μg/mL
kanamycin and grown at 37 °C overnight. The 15 mL
bacterial solution was inoculated into 2 L LB medium
containing 50 μg/mL kanamycin in a shaker at 37 °C
until the A600 of culture reached to 0.8–0.9. Following
induction with 1 mM isopropyl-β-D-thiogalactopyrano-
side (IPTG) for 4 h at 37 °C with 200 rpm shaking, cells
were harvested by centrifugation at 8, 000 g, 4 °C for 20
min and washed with cold phosphate buffered saline
(PBS, 8 g/L NaCl, 3.63 g/L Na2HPO4•12 H2O, 0.2 g/L
KCl and 0.24 g/L KH2PO4, pH = 8.0). The pellets were
resuspended in lysis buffer (PBS with 5 mM β-
mercaptoethanol, 1 % (w/v) sodium deoxycholate and 1
mM PMSF, pH = 8.0) at a ratio of 1:5 (w/v) and lysed
using ultrasound. The sonicated cell suspensions were
isolated by centrifugation at 12, 000 g and 4 °C for
30 min, and the supernatant and pellet were applied
to 10 % sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS-PAGE) to determine the recom-
binant protein solubility and expression level. Gels
were scanned using Canon CanoScan 9000F Mark II
scanner. The absolute integrated optical density of
each band was quantitated using GelPro Analyzer
software from Media Cybernetics (Des Moines, IA).
The ratio of target protein to the total proteins repre-
sented the enrichment of GBP-SubA fusion protein.
GBP-SubA purification and refolding
The insoluble fraction containing GBP-SubA was
washed three times in wash buffer (PBS with 4 M urea
and 1 % Triton X-100, pH = 8.0) to remove as much
contaminants as possible. Then, the insoluble fraction
containing GBP-SubA was resuspended in extraction
buffer (PBS with 6 M guanidine-HCl, 0.5 M NaCl, 20
mM imidazole and 5 mM β-mercaptoethanol, pH = 8.0)
and dissolved overnight at 4 °C. The dissolved solution
of precipitate was centrifuged at 12, 000 g for 30 min to
remove any insoluble debris. The supernatant was mixed
with Ni Sepharose 6 Fast Flow (GE healthcare) which
had been pre-equilibrated with extraction buffer and
shaken gently overnight at 4 °C. The mixture was loaded
on a PD-10 column (GE healthcare). The column was
then washed with 40 mL extraction buffer, followed by
30 mL elution buffer A (PBS with 8 M urea, 0.5 M NaCl,
20 mM imidazole and 5 mM β-mercaptoethanol, pH =
8.0), and then 20 mL elution buffer B (PBS with 8 M
urea, 0.5 M NaCl, 20 mM imidazole and 5 mM β-
mercaptoethanol, pH = 6.3). The GBP-SubA was then
eluted with a gradient of 0–500 mM imidazole in elution
buffer B. The eluted protein solutions were collected
and analyzed by SDS-PAGE.
The purified GBP-SubA was dialyzed at 4 °C. Briefly,
the denatured GBP-SubA was refolded by dialysis
against 200 mL elution buffer A to 800 mL of refolding
buffer (PBS with 0.1 mM glutathione, 0.01 mM glutathi-
one disulfide, 1 mM EDTA, 0.15 M L-arginine and 5 %
(v/v) glycerol, pH = 8.0), which was added dropwise at a
rate of 100 mL/h. This was followed by dialysis against
three changes of refolding buffer. At last, the GBP-SubA
solution dialysised against 2 L PBS. The purity of GBP-
SubA was judged by SDS-PAGE after staining with coo-
massie brilliant blue R-250 and AgNO3. Concentration
of refolded GBP-SubA was determined by BCA protein
assay kit (Beyotime, Jiangsu, China).
Flow cytometric assay of cell surface GRP78
and cell apoptosis
The expression of GRP78 on cell surfaces was evalu-
ated by flow cytometry. HL-7702, DLD1 and HepG2
cells were collected using cell scrapers after double
washes in PBS, and then cells were pipetted dozens to
make single-cell suspension. After centrifugation at 300
g for 5 min at room temperature, cells were incubated
with anti-GRP78 primary antibodies and sequentially
phycoerythrin-conjugated secondary antibodies. Each
of antibodies was incubated at 37 °C for 1 h in dark,
and gently mixed cells every 10 min during this pro-
cedure. Cells were washed triple and loaded onto a
Guava PCA flow cytometer (Millipore, USA) to meas-
ure, at least 20, 000 cells were counted per sample, and
data were analyzed and exported by CytoSoft 6.0.2.
The apoptosis of cells with GBP-SubA treatment
was evaluated by flow cytometry. HL-7702, DLD1 and
HepG2 cells were added to 60-mm culture plates at a
density of 106 cells per dish and incubated overnight
at 37 °C in 5 % CO2. The purified 0.1 μg/mL GBP-
SubA was added to each dish and incubated for 48 h.
In the GRP78-blocking assay, the antibody of GRP78
was add in the cell medium to incubate for 1 h, and
then added GBP-SubA. At last, the cells were harvested
and operated according the instruction of Guava Nexin
Reagent.
Western blotting
For western blotting, after appropriate treatments, ly-
sates of cells were prepared and centrifuged at 13, 000 g
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at 4 °C to remove cell debris. 80 μg of the obtained
supernatant proteins were mixed with 5× SDS sample
buffer, and boiled for 5 min. After the samples had been
separated, the proteins on the gel were transferred
onto a PVDF membrane. After blocking in 5 % skim
milk for 1 h, the membranes were incubated overnight at
4 °C with the appropriate diluted primary antibodies,
followed by incubation with HRP-conjugated secondary
antibody at 37 °C for 2 h. The bands were visualized using
an enhanced chemiluminescence detection kit and radio-
graphic film exposure. Documentation of blots was per-
formed by Canon CanoScan 9000F Mark II scanner.
Immunofluorescence analysis of cytoplasmic GBP-SubA
In the process of cytoplasmic GBP-SubA staining, HL-
7702, DLD1 and HepG2 Cells were plated on 12-well glass
slides, and treated with 0.1 μg/mL GBP-SubA for 12 h. In
the GRP78-blocking assay, the antibody of GRP78 was add
in the cell medium to incubate for 1 h, and then added
GBP-SubA. After treatments, the cells were fixed in Immu-
nol Staining Fix Solution overnight at 4 °C, and perme-
abilized in PBS containing 0.3 % Triton X-100 for 10 min.
Next, slides were blocked in PBS containing 5 % bovine
serum albumin (BSA) for 30 min at 37 °C, and incubated
with the anti-His-tag antibodies at 4 °C overnight. Slides
were then washed and incubated with corresponding
FITC-conjugated secondary antibodies and Rhodamine-
conjugated Phalloidin. Nucleus was identified by
staining with DAPI. After three washes of PBS, slides
were mounted in gelvatol for immunofluorescence
analysis. All images were obtained by DeltaVision Per-
sonal microscope (Applied Precision Inc.).
Cell proliferation assay
For MTT assay, HL-7702, DLD1 and HepG2 cells were
added to 96-well culture plates at a density of 104 cells
Fig. 1 Construction of the recombinant plasmid pET-28a-GBP-SubA. a. Both pET-28a and pMD19-GBP-SubA plasmids were digested by Bam HI
and Xho I. Lane 1: pET-28a vector (after digestion); lane 2: pMD19-GBP-SubA plasmid (after digestion). b. GBP-SubA was successfully inserted into
pET-28a vector confirmed by colony PCR. Lane 1: PCR products amplified by GBP-SubA primers. c. Both pET-28a and recombinant pET-28a-GBP-SubA
were digested by Bam HI or/and Xho I. Lane 1: pET-28a vector (before digestion); lane 2: recombinant pET-28a-GBP-SubA (digested with Bam HI only);
lane 3: recombinant pET-28a-GBP-SubA (digested with Bam HI and Xho I); Lane M: marker
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per well and incubated overnight at 37 °C in 5 % CO2.
The purified recombinant GBP-SubA in different con-
centrations were added to each well, and PBS was used
as the control. In the GRP78-blocking assay, before the
0.1 μg/mL GBP-SubA was added in the medium, the
antibody of GRP78 was added and incubated for 1 h.
After 48 h incubation, 20 μL (final concentration is 0.5
mg/mL) 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetra-
zolium bromide (MTT) was added to each well and incu-
bated for 4 h at 37 °C. The solution was discarded and 100
μL DMSO was added to each well. After shaking gently
for 10 min, the plate was read at 570 nm using TECAN
infinite M200 Pro microplate spectrophotometer.
For cytometry assay, HL-7702, DLD1 and HepG2
cells were added to 12-well culture plates at a density
of 5 × 104 cells per well and incubated overnight at
37 °C in 5 % CO2. Then 0.1 μg/mL GBP-SubA was
added to the well, and PBS was used as the control.
After 48 h of incubation, the cells were collected by
trypsinization and counted with hemacytometer.
TUNEL and DAPI staining
TUNEL staining data were obtained using a commercial
kit (Cat. No. KGA7071, KeyGEN BioTECH, Nanjing,
China). Briefly, HL-7702, DLD1 and HepG2 Cells were
plated on 12-well glass slides. After treatments with 0.1
μg/mL GBP-SubA for 48 h, the cells were fixed in 4 %
paraformaldehyde for 30 min, and permeated with Pro-
teinase K solution for 30 min. Then slides were incu-
bated in TUNEL reaction mixture containing terminal
Fig. 2 Expression of GBP-SubA. a. E. coli Rosetta (DE3) containing pET-28a or pET-28a-GBP-SubA was induced by 1 mM IPTG at 37 °C for 4 h, and
then lysed with ultrasound. Lane 1, 3 and 5: the total cellular lysate, soluble lysate fraction and insoluble lysate fraction from E. coli Rosetta (DE3)
containing pET-28a plasmid, respectively; lane 2, 4 and 6: total cellular lysate, soluble lysate fraction and insoluble lysate fraction from E.
coli Rosetta (DE3) containing pET-28a-GBP-SubA plasmid, respectively; Lane M: marker. b. Induction of GBP-SubA with different concentrations of IPTG
at 37 °C. lane 1–3: total cellular lysate, soluble lysate fraction and insoluble lysate fraction of E. coli Rosetta (DE3) containing pET-28a-GBP-SubA plasmid
that induced by 0.1 mM IPTG; lane 4–6: total cellular lysate, soluble lysate fraction and insoluble lysate fraction of E. coli Rosetta (DE3)
containing pET-28a-GBP-SubA plasmid that induced by 0.5 mM IPTG; lane 7–9: total cellular lysate, soluble lysate fraction and insoluble
lysate fraction of E. coli Rosetta (DE3) containing pET-28a-GBP-SubA plasmid that induced by 1 mM IPTG; lane 10–12: total cellular lysate,
soluble lysate fraction and insoluble lysate fraction of E. coli Rosetta (DE3) containing pET-28a-GBP-SubA plasmid that induced by 2 mM
IPTG; Lane M: marker. c. Induction of GBP-SubA with different concentrations of IPTG at 16 °C. Lane 1–2: soluble lysate fraction and insoluble lysate
fraction of E. coli Rosetta (DE3) containing pET-28a-GBP-SubA plasmid that induced by 0.1 mM IPTG; lane 3–4: soluble lysate fraction and insoluble lysate
fraction of E. coli Rosetta (DE3) containing pET-28a-GBP-SubA plasmid that induced by 0.5 mM IPTG; lane 5–6: soluble lysate fraction and insoluble lysate
fraction of E. coli Rosetta (DE3) containing pET-28a-GBP-SubA plasmid that induced by 1 mM IPTG; lane 7–8: soluble lysate fraction and insoluble lysate
fraction of E. coli Rosetta (DE3) containing pET-28a-GBP-SubA plasmid that induced by 2 mM IPTG; Lane M: marker
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deoxynucleotidyl transferase (TDT) for 60 min at 37 °C.
The slides were then washed in PBS for three times, coun-
terstained with 4′,6-diamidino-2-phenylindole (DAPI) for
10 min, and rinsed with PBS. The sections were analyzed
under a fluorescent microscope. In the GRP78-blocking
assay, before the 0.1 μg/mL GBP-SubA was added in the
medium, the antibody of GRP78 was added and incubated
for 1 h.
Statistical analysis
Data were expressed as the mean ± SEM. Differences
among groups were tested by one-way analysis of vari-
ance (ANOVA). Comparisons between two groups were
evaluated using Student’s t-test. A value of p < 0.05 was
considered statistically significant.
Results
Plasmid construction and expression of GBP-SubA
To get the gene of SubA, we commissioned TaKaRa
Biotechnology Company to synthesize and insert it into
T-Vector pMD19. The synthesized DNA was 1089 bp
and encoded an ORF of 355 amino acid residues that
included eight amino acids of GBP. Subsequently, the
pMD19-GBP-SubA and pET-28a vector were digested
by restriction enzyme to release the GBP-SubA insert
and prepare the vector for ligation and transformation
(Fig. 1a). The recombinant plasmid pET-28a-GBP-SubA
was successfully constructed and confirmed by colony
PCR (Fig. 1b, the primers were listed in Additional file 1:
Table S1), restriction digestion (Fig. 1c) and DNA
sequencing.
To obtain the fusion proteins of GBP-SubA, we trans-
fected the recombinant plasmid pET-28a-GBP-SubA
into E. coli Rosetta (DE3) cells, and the cells were in-
duced by 1 mM IPTG at 37 °C for 4 h. However, most
of target proteins were found in the insoluble fraction
after the centrifugation following the cell lysis (Fig. 2a).
Several other expression parameters, including IPTG
concentrations and incubation temperatures, were
assessed, but none of them can increase the soluble or
insoluble expression of GBP-SubA (Fig. 2b and c). So
the above expression condition was chosen to obtain in-
clusion bodies, and the denaturation and renaturation
were followed.
Purification of GBP-SubA
Next, the collected inclusion bodies were purified by
wash buffer (containing 4 M urea). The results showed
Fig. 3 Purification and refolding of GBP-SubA. a. After three washes with PBS, the irrelevant proteins of insoluble lysate fraction reduced. Lane 1 and 2:
supernatant and pellet after the 1st wash; lane 3 and 4: supernatant and pellet after the 2nd wash; lane 5 and 6: the supernatant and pellet after the
3rd wash; Lane M: marker. b. GBP-SubA proteins were eluted by a gradient concentration of imidazole from nickel ion-chelated beads. Lane 1–3: the
protein eluted by 50 mM imidazole; lane 4–6: the protein eluted by 100 mM imidazole; Lane 7–9: the protein eluted by 200 mM imidazole; Lane 10–12:
the protein eluted by 300 mM imidazole; Lane 13–15: the protein eluted by 500 mM imidazole; Lane M: marker. c. Refolded-GBP-SubA protein
was analyzed by SDS-PAGE and coomassie brilliant blue R-250 stain. Lane 1: the GBP-SubA protein after refolding; Lane M: marker. d. Refolded-GBP-
SubA protein was analyzed by SDS-PAGE and silver stain. Lane 1: the GBP-SubA protein after refolding; Lane M: marker
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that irrelevant proteins were reduced significantly after
three washes, and the loss from above procedure on
GBP-SubA inclusion bodies was quite small (Fig. 3a).
After dissolution with extraction buffer (containing 6 M
guanidine-HCl) overnight at 4 °C, the GBP-SubA solu-
tion was loaded onto Ni-NTA resin and a series of
elution buffers (contain 8 M urea and gradient imidazole
concentrations) were used to elute this protein. The re-
sults showed that GBP-SubA was mainly eluted by elu-
tion buffer containing 200 mM imidazole, a few proteins
were found in the 300 and 500 mM imidazole elution
buffer, so the GBP-SubA in 200, 300 and 500 mM imid-
azole elution buffer were collected for the further rena-
turation process (Fig. 3b).
The denatured GBP-SubA was refolded by dialysis
against elution buffer (without imidazole) to which PBS
was added dropwise. After the concentration of urea
reached to 0.01 M, the refolding buffer was replaced by
PBS and continued to dialyze 12 h, at last, the yield of
the refolded proteins was 3.5 mg of 1 L culture. The
purity of the refolded proteins in PBS was more than
99 %, which was determined by coomassie blue stain
and silver stain after SDS-PAGE (Fig. 3c and d).
The dual bioactivity assays of the recombinant
fusion proteins
The best way to examine the dual bioactivities of re-
combinant GBP-SubA is to detect whether the GBP-
SubA can enter into the cells with surface-GRP78, and
whether the entered GBP-SubA can cleave the intracel-
lular GRP78. In order to achieve these, two tumor cell
lines (DLD1 and HepG2) and one normal cell line (HL-
7702) were selected by flow cytometry firstly. As shown
in Fig. 4a and b, tumor cell (DLD1 and HepG2) surface
GRP78 is more than the normal cells, and more GRP78
were detected on HepG2 cells surface than that on
DLD1. Moreover, the fluorescence intensity of HL-7702
cells was similar with the negative control, suggesting
that the GRP78 was almost nonexistent on HL-7702
cell surface. Next, the total membrane proteins of the
three cell lines were extracted and subjected to western
blotting analysis. As shown in Fig. 4c, in the case of
equal protein loading, surface GRP78 level of HepG2
cells was higher than that of DLD1 cells, and the
GRP78 on HL-7702 cell surfaces was barely detect-
able. So the HL-7702, DLD1 and HepG2 were used
as typical cells without cell surface GRP78, with little
Fig. 4 Detection of cell surface GRP78. a. The surface-GRP78 of HL-7702, DLD1 and HepG2 cells were stained by anti-GRP78 antibody and
analyzed by flow cytometry, and the HL-7702 stained with IgG served as the negative control. b. The mean fluorescence intensity of
HL-7702, DLD1 and HepG2 cells stained with anti-GRP78 antibody and the negative control stained with IgG. c. Cell membrane proteins
were extracted from HL-7702, DLD1 and HepG2 cells. Equal amount of protein was loaded per lane for western blotting detection of GRP78
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cell surface GRP78 and with a lot of cell surface
GRP78, respectively.
To analyze the cellular entry of GBP-SubA and the
cleavage of GRP78, different doses of GBP-SubA were
applied to above three cell lines in culture for 24 h. The
total proteins of cells were extracted and analyzed by
western blot. As shown in Fig. 5a, a number of GBP-
SubA were detected by His-tag antibodies in HepG2
cells even at the minimum concentration of 0.001
μg/mL, the GBP-SubA in DLD1 cells also showed a
dose-dependent increase. However, only a little GBP-
SubA entered HL-7702 cells even at the concentra-
tion of 1 μg/mL. Simultaneously, the cleavage of
GRP78 was analyzed by polyclonal anti-GRP78 anti-
bodies. The GRP78 antibody labelled a 78 kD band
in the lysates of untreated cell. By contrast, the lysate
of cells treated with GBP-SubA had a markedly
diminished 78 kD band, and a new band occurred at
28 kD. Along with the increase of intracellular GBP-
SubA, GRP78 was cleaved in DLD1 and HepG2 cells
more and more significantly, whereas the GRP78 was
just slightly cleaved even at the concentration of 1
μg/mL in HL-7702 cells (Fig. 5a).
In order to evaluate the inhibition effect of GBP-SubA
on tumor cells, MTT assays were performed with HL-
7702, DLD1 and HepG2 cells. As shown in Fig. 5b,
GBP-SubA could suppress the proliferation of HepG2
and DLD1 cells but not for HL-7702 cells. At the
concentration of 0.1 μg/mL, the inhibition rates of GBP-
SubA on HepG2 and DLD1 were 60 % and 47 %,
respectively, whereas the HL-7702 cells were not
affected conspicuously. In addition, the cytometry was
applied to further verify the inhibition effect of 0.1
μg/mL GBP-SubA on tumor cells. The results revealed
that the proliferation of tumor cells were specifically
inhibited with 0.1 μg/mL GBP-SubA treatment, and the
normal cells were not affected (Fig. 5c). These results sug-
gested that the SubA and GBP retained their bioactivity
after fusion and renaturation. 0.1 μg/mL was the suitable
dose for targeting antitumor activity of GBP-SubA. So the
concentration of 0.1 μg/mL of GBP-SubA was selected to
perform the following experiments.
Apoptosis-induction effect of GBP-SubA on tumor cells
To further detect the antitumor activity of recombinant
GBP-SubA, we firstly examined the ability of GBP-SubA
to enter cells at the concentration of 0.1 μg/mL by
immunofluoresence staining. As described in Fig. 6a,
GBP-SubA was detectable and predominantly presented
in both DLD1 and HepG2 cells after incubated with
Fig. 5 The cleavage of GRP78 and inhibition of tumor cells by GBP-SubA. a. The total cellular lysate was extracted from HL-7702, DLD1 and
HepG2 cells that were treated with different concentrations of GBP-SubA for 24 h, and the cleavage of GRP78 was analyzed by western blotting.
b. Cell inhibition ratios of GBP-SubA were determined by the MTT assay. HL-7702, DLD1 and HepG2 cells were incubated with different concentrations
of GBP-SubA for 48 h. *p < 0.05, **p < 0.01, compared with the control. c. The cellular inhibition of GBP-SubA was determined by cytometry. HL-7702,
DLD1 and HepG2 cells were incubated with 0.1 μg/mL GBP-SubA for 48 h. *p < 0.05, **p < 0.01, compared with the control
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Fig. 6 (See legend on next page.)
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GBP-SubA for 12 h, while there was no visible GBP-
SubA in HL-7702 cells.
Next, the flow cytometric was applied to analyze the
apoptosis-induction effect of GBP-SubA. As shown in
Fig. 6b, GBP-SubA could induce 55 % HepG2 cells and
40.9 % DLD1 cells apoptosis (including early and late
stage apoptosis), but the apoptosis rate was only 6 % in
GBP-SubA-treated HL-7702 cells, which was close to
the control (Fig. 6b). The results above implicated that
GBP-SubA could specifically enter cancer cells and in-
duce apoptosis.
Verification of GBP-SubA bioactivity by blocking cell
surface GRP78
Theoretically, GBP-SubA could cleave the cell sur-
face GRP78 at the COOH-terminal, which was the
same as SubA [21]. Thus, to further verify the bio-
activity of GBP-SubA on tumor cells, we blocked the
tumor cell surface-GRP78 with antibody that against
NH2-terminal of GRP78, and then detected the
proliferation-inhibition effect, the cellular entry and
the apoptosis-induction effect of GBP-SubA. The results
of MTT assay showed that blocking cell surface-GRP78
reversed the proliferation-inhibition effect induced by
GBP-SubA (Fig. 7a). Moreover, the amount of GBP-SubA
getting into DLD1 and HepG2 cells was reduced signifi-
cantly with the presence of anti-GRP78 antibody (Fig. 7b).
Meanwhile, these cells were stained using TUNEL and 4,
6-diamidino-2-phenylindole dihydrochloride (DAPI) to
show apoptotic morphology after incubation with GBP-
SubA for 48 h. As illustrated in Fig. 7c, the HepG2 and
DLD1 cells showed typical apoptotic nuclear changes, and
the numbers of apoptotic bodies and TUNEL-positive nu-
clei in HepG2 were more than that in DLD1, and blocking
surface-GRP78 could reverse the nuclear changes that
were induced by GBP-SubA. However, GBP-SubA exerted
very little effect on HL-7702 cells. Accordingly, the apop-
tosis rate of DLD1 and HepG2 fell to 12.2 % and 14.2 %,
respectively (Fig. 7d). These results further demonstrated
that GBP-SubA possessed the dual efficacy of targeting
and killing tumor cells by against GRP78 only.
Discussion
SubAB has been famous for high pathopoiesia since it
was discovered. However, it is reported that nearly all
toxins of bacterial or plant can be explored for tumor
therapy through suitable modification, such as truncated
diphtheria toxin (DT) or Shiga-like toxin (StxA), work-
ing through the inhibition of protein synthesis [22]. The
ubiquitous receptor of B subunit handicaps the applica-
tion of SubAB severely [23], so a tumor-specific assistant
is necessary for the antitumor application of SubA.
Epidermal growth factor (EGF) is the first ligand that is
used to improve tumor cells specificity of SubA for the
overexpression of epidermal growth factor receptor
(EGFR) on tumor cell surface [24]. Nevertheless, EGFR
not only presents on tumor cell surface, it also controls
many different processes in normal tissues and cells,
such as the differentiation and proliferation of astrocytes
at late embryonic and neonatal stages of cortical devel-
opment [25], the efficient differentiation of mesenchymal
cells in the semilunar valves of the heart [26], as well as
the cell proliferation and cell-cycle entry of hepatocytes
following tissue injury [27], all of which limit the clinical
applications of EGF-SubA.
GRP78 frequently locates on cell membranes of cancer
cells but absent on those of normal cells, suggesting that
tumor-targeted therapy via cell surface GRP78 is feas-
ible. In this study, we chose GRP78 that is more specific
distribution on tumor cell surface as the receptor, and
GBP was employed as the ligand of GRP78, which is
ligated to SubA to achieve targeting antitumor. The
present data implied that the fusion protein GBP-SubA
exhibited strong antitumor activities.
The ligand peptides GBP (WIFPWIQL) was designed
to identify the cell surface GRP78 and perform further
cell internalization. However, the specific interaction
sites of GBP and GRP78 were still unknown. It has been
reported that SubA is able to cleave cell surface GRP78
between the amino acid residues Leu416 and Leu417 and
release the 28 kD COOH-terminal fragment of GRP78,
which will abrogate the COOH-terminal domain signal
transduction, whereas the NH2-terminal domain ligation
is unaffected [21]. Logically, the GBP-SubA is also able
to cleave the cell surface GRP78 as the same as SubA. If
the interaction sites of GBP and GRP78 locate at the
COOH-terminal fragment of GRP78, the fusion protein
of GBP-SubA is impossible to display its function. Fortu-
nately, our results clearly showed that the GBP-SubA
was able to enter into the tumor cells, and the amount
of GBP-SubA in cells was increased along with the
enhanced cell surface GRP78, furthermore, blocking
NH2-terminal of GRP78 with antibody could reduce
GBP-SubA entry efficiency and reverse the proliferation-
(See figure on previous page.)
Fig. 6 The apoptosis of tumor cells induced by GBP-SubA. a. HL-7702, DLD1 and HepG2 cells were incubated with 0.1 μg/mL GBP-SubA for 12 h.
The entry of GBP-SubA to cells was analyzed by immunofluorescence. The GBP-SubA was stained by anti-His-tag primary antibody and FITC-
conjugated secondary antibody, the actin was stained by Rhodamine-conjugated Phalloidin, and the nucleus was stained by DAPI. b. HL-7702,
DLD1 and HepG2 cells were incubated with 0.1 μg/mL GBP-SubA for 48 h, the control was treated with PBS, and the apoptosis was analyzed
by flow cytometry
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Fig. 7 Verification of GBP-SubA bioactivity by blocking cell surface GRP78. a. After blocking cell surface GRP78, the cell inhibition ratios of GBP-
SubA were determined by the MTT assay. HL-7702, DLD1 and HepG2 cells were incubated with or without anti-GRP78 antibody 1 h, and then 0.1
μg/mL GBP-SubA was added in the medium to incubate for another 48 h. *p < 0.05, **p < 0.01, compared with the control. b. After blocking cell
surface GRP78, the cellular entry of GBP-SubA was detected by immunofluorescence. DLD1 and HepG2 cells were incubated with anti-GRP78
antibody 1 h, and 0.1 μg/mL GBP-SubA was then added in the medium to incubate for another 12 h. c. HL-7702, DLD1 and HepG2 cells were
incubated with 0.1 μg/mL GBP-SubA for 48 h. For antibody blocking groups, the anti-GRP78 was added 1 h earlier. The nucleus morphology
of apoptotic cells was observed by TUNEL and DAPI staining. d. After blocking cell surface GRP78, the apoptosis-induction effect of GBP-SubA
was analyzed by flow cytometry. DLD1 and HepG2 cells were incubated with anti-GRP78 antibody 1 h, and 0.1 μg/mL GBP-SubA was then
added in the medium to incubate for another 48 h. The control was without GBP-SubA and anti-GRP78 treatment
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inhibition and the apoptosis-induction effects of GBP-
SubA. Consequently, our results implied that the
interaction sites of GBP and GRP78 may locate at the
NH2-terminal of GRP78.
The main function of GBP (WIFPWIQL) in GBP-
SubA is to identify the cell surface GRP78. The GBP
composed of only eight amino acids, whether the tag for
affinity purification blocked the function of GBP kept us
concerned. It has been reported that the trypsin inhibi-
tor fused with GBP and GST tag was able to bind to cell
surface GRP78, which verified that the GST tag had no
effect on the function of GBP [28]. We therefore specu-
lated that His tag will have minimal effect on fusion pro-
tein, because 6× His is the minimum tag for protein
purification. Based on this idea, we constructed GBP-
SubA with pGEX-4T-1 vector and pET-28a vector,
respectively. Our experiment further showed that the
GBP-SubA with GST-tag was expressed as inclusion
bodies in E. coli BL21 (DE3) cells, and the GBP-SubA
with His-tag could not express in E. coli BL21 (DE3)
cells (Additional file 1: Figure S1a and S1b). Moreover,
we transfected the two recombinant plasmids into E. coli
Rosetta (DE3), and found that both GBP-SubA of His-
tagged and GST-tagged were able to express in Rosetta
cells (Fig. 2a and Additional file 1: Figure S1c), but both
of them expressed the fusion proteins as inclusion bod-
ies. The GBP-SubA with His-tag was chosen to apply
the denaturation and renaturation procedure due to its
convenience of operations. As expected, through de-
naturation, purification and refolding, the His-GBP-
SubA could enter into cells successfully, demonstrating
that the His-tag had no effect on the function of GBP.
Aggregation of inclusion bodies is the major problem
in the refolding procedure of denatured recombinant
proteins. It had been reported that glycerol was able to
increase the stability of proteins and aid proteins to re-
fold [29]. In addition, cysteine residues could form inter-
or intra-disulfide bonds that may lead to aggregation
[30]. There are two cysteine residues in SubA that are
going to form one disulfide bond (data from NCBI pro-
tein: 2IY9_A). Therefore, 5 % (v/v) glycerol and GSH/
GSSG were added in the refolding buffer to facilitate the
proper renaturation of GBP-SubA. During the refolding
process, the renaturation rate is very important for the
formation of native structure of protein. In order to slow
down the rate of urea decrease in refolding buffer, the
PBS was added dropwise at a rate of 100 mL/h. At last,
3.5 mg renatured GBP-SubA was obtained from 1 L
culture.
Conclusions
We successfully obtained the fusion protein GBP-SubA
through expression, denaturation and renaturation. The
GBP-SubA remained dual functions of both GBP and
SubA. The obtained fusion protein was able to enter into
cells by surface GRP78 and cleave intracellular GRP78,
which induced tumor cells apoptosis. Therefore, the
targeted suppression on tumors was achieved by GBP-
SubA, which implied that GBP-SubA was suitable to
development for antitumor drugs.
Additional file
Additional file 1: Supplemental data. The sequence of primers for
GBP-SubA and optimization of E. coli strain and vector of GBP-SubA
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